Pemphigus Foliaceous after COVID-19 Infection and Bamlanivimab Infusion

Main Article Content

Katelyn Urban
Rachel L. Giesey
Gregory R. Delost


pemphigus foliaceus, COVID-19, sars-cov-2


We report a case of pemphigus foliaceous (PF) in the setting of bamlanivimab, a novel monoclonal antibody for the treatment of COVID-19. PF is a rare autoimmune blistering disease caused by autoantibodies directed against desmoglein-1 (DSG1). Drugs and viruses have been implicated as inciting factors of pemphigus in predisposed patients. Given the current pandemic, the presentation of PF following COVID-19 infection and bamlanivimab infusion is of special interest and further investigation may be warranted.


1. An EUA for Bamlanivimab-A Monoclonal Antibody for COVID-19. JAMA. 2021 Mar 2;325(9):880-881.

2. Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019 Sep 7;394(10201):882-894.

3. James KA, Culton DA, Diaz LA. Diagnosis and clinical features of pemphigus foliaceus. Dermatol Clin. 2011;29(3):405-viii.

4. Melchionda V, Harman KE. Pemphigus vulgaris and pemphigus foliaceus: an overview of the clinical presentation, investigations and management. Clin Exp Dermatol. 2019 Oct;44(7):740-746.

5. Palleria C, Bennardo L, Dastoli S, Iannone LF, Silvestri M, Manti A, Nisticò SP, Russo E, De Sarro G. Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers induced pemphigus: A case series and literature review. Dermatol Ther. 2019 Jan;32(1):e12748.

6. Brenner S, Goldberg I. Drug-induced pemphigus. Clin Dermatol. 2011 Jul-Aug;29(4):455-7.

7. Ruocco E, Wolf R, Ruocco V, Brunetti G, Romano F, Lo Schiavo A. Pemphigus: associations and management guidelines: facts and controversies. Clin Dermatol. 2013 Jul-Aug;31(4):382-390.

8. Munavalli GG, Knutsen-Larson S, Lupo MP, Geronemus RG. Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin II-induced cutaneous inflammation. JAAD Case Rep. 2021 Apr;10:63-68.

9. Beyzaee AM, Rahmatpour Rokni G, Patil A, Goldust M. Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review. Dermatol Ther. 2021;34(1):e14405.

10. Kim, A., Khan, M., Lin, A., Wang, H., Siegel, L., & Rozenberg, S. (2021). New Bullous Eruptions in a COVID-19 Positive Patient in an Intensive Care Unit. SKIN The Journal of Cutaneous Medicine, 5(3), 278–282.